Research

Hormonal

Treatment with tirzepatide (10 or 15 mg) produces a significantly greater reduction in predicted 10-year cardiovascular disease (CVD) risk compared to semaglutide (1.7 or 2.4 mg) in individuals with obesity without diabetes or prior CVD.

If you have obesity and are at risk for heart disease but don't have diabetes, tirzepatide may offer better long-term heart protection than semaglutide. It is taken as a weekly injection and has been shown to reduce your predicted 10-year risk of cardiovascular events more than semaglutide. Discuss with your doctor if this medication is appropriate for your specific health profile.

GoodSupportsHIGH confidence
Treatment with tirzepatide was associated with significantly greater reduction in predicted 10-year CVD risk compared with semaglutide (absolute reduction from baseline of 2.4% and 1.4%, respectively, P < 0.001).
Mamas Mamas et al. · European Heart Journal Open · 2025

Why this rating

Based on a Phase 3b randomized controlled trial (SURMOUNT-5), though the CVD risk is a predicted score rather than observed clinical events.

Source

Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: <i>post-hoc</i> analysis of the SURMOUNT-5 trial

Mamas Mamas et al. · European Heart Journal Open · 2025

DOI 10.1093/ehjopen/oeaf117

rct · n=576Cited 11×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →